Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Maze Therapeutics announced positive topline results from its Phase 2 HORIZON trial showing clinical proof-of-concept for MZE829 in APOL1-mediated kidney disease (AMKD). The company plans to advance MZE829 into pivotal trials and start two Phase 2 trials in 2026 for MZE782 targeting phenylketonuria (PKU) and chronic kidney disease (CKD). Maze also …